医学
头孢曲松
溶血性贫血
贫血
肝炎
血红蛋白
病毒学
免疫学
内科学
微生物学
抗生素
生物
作者
Michael J. Bell,David C. Stockwell,Naomi L.C. Luban,R. Sue Shirey,Lorraine Shaak,Paul M. Ness,Edward C.C. Wong
出处
期刊:Pediatric Critical Care Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2005-04-29
卷期号:6 (3): 363-366
被引量:40
标识
DOI:10.1097/01.pcc.0000161285.12396.ff
摘要
To describe a case of a ceftriaxone-induced hemolytic anemia and hepatitis leading to multiple organ failure and death in an adolescent with hemoglobin SC disease and to review the previous cases of this rare and potentially fatal disorder in children.Case report and literature review.Intensive care unit.Adolescent with hemoglobin SC.Emergency treatment.After 4 days of ceftriaxone therapy, the adolescent experienced an acute hemolytic reaction (hemoglobin decreased to 5 g/dL with hemoglobinuria) and severe hepatitis (all enzymes increasing dramatically including aminoaspartate transferase >20,000 IU/L). Renal failure and ultimately multiple organ failure ensued, and the patient died on hospital day 19. Direct antiglobulin tests on red cells obtained from the patient on hospital day 2 showed microscopic agglutination with polyspecific and anticomplement (C3) antiglobulin reagents. Plasma samples showed macroscopic agglutination reactions when incubated in the presence of ceftriaxone, many days after cessation of ceftriaxone, indicating the continued presence of ceftriaxone-dependent antibodies.Drug reactions leading to hemolysis are relatively uncommon, and a total of ten cases of ceftriaxone-induced hemolytic anemia have been reported in children. The present case describes an adolescent who ultimately died on hospital day 19 from multiple organ failure, although the presentation of this case seems atypical in several respects. Children with clinical syndromes that place them at risk for hemolysis and children who frequently require broad spectrum antibiotics present unique diagnostic challenges, and the possibility that hemolytic syndromes may be due to ceftriaxone must be considered.
科研通智能强力驱动
Strongly Powered by AbleSci AI